The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Clinical Roundup

Roswell Park moves forward with expanded study of CIMAvax

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Final results from the first U.S. clinical study of a Cuban immunotherapy show that CIMAvax-EGF, a treatment targeting a particular cancer survival protein, epidermal growth factor, is safe and showed promising efficacy as part of a treatment combination with nivolumab (Opdivo) in patients with advanced non-small cell lung cancer.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

PodcastThe Directors

The Directors: Two leaders in data science have a warp speed vision for AI, with cancer clinical trials leading the way
Knudsen and Thoelke: “It’s actually solving for bottlenecks and challenges that we’ve been unable to overcome for so long”

The United States has a translation problem. Scientific breakthroughs in oncology are accelerating, but clinical trial infrastructure hasn’t kept pace. 
By Paul Goldberg and Claire Marie Porter
Guest Editorial

Cancer progress is not reaching everyone. Native Nations must be part of the solution.

In 1971, the National Cancer Act set the United States on a path to confront one of its most formidable public health challenges. More than five decades later, the progress is undeniable. The latest 2026 report from the American Cancer Society shows continued declines in overall cancer mortality and improvements in survival for many major cancer types. Recent advances in early detection, prevention, and treatment are saving lives.
By Rodney Haring
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account